Observational data shows improved health outcomes with pembrolizumab in earlier-stage cancers, indicating reduced productivity loss for caregivers.
Perioperative/adjuvant pembrolizumab in earlier-stage cancers can meaningfully improve clinical outcomes for Medicare patients and reduce caregiver productivity losses. Sustained investment and access to pembrolizumab are critical to fully realize these benefits for patients and society.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: